NCT04901754 2021-12-08
CAMERA
Henan Cancer Hospital
Phase 2 Unknown
Clinical Trials
11 trialsNCT04490421 2021-02-08
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Fuzhou General Hospital
Phase 3 Unknown
NCT04683198 2020-12-24
Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
ChineseAMS
Phase 2 Unknown
NCT04659785 2020-12-09
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
Tianjin Medical University Second Hospital
Phase 1/2 Unknown
NCT03389087 2020-07-10
Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT04453930 2020-07-01
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04128800 2019-10-16
Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03651219 2018-08-29
Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer
Beijing Chest Hospital
Phase 3 Unknown
NCT03135977 2017-12-07
Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT02995187 2017-09-07
Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)
ChineseAMS
Phase 2 Unknown
NCT02980809 2016-12-02
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
First Hospitals affiliated to the China PLA General Hospital
Phase 2 Unknown